SCHEMBL4984420

SCHEMBL4984420

C=CCNc1nnc(Cl)c2cc(C(=O)O)ccc12

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.60
HPGD P15428 4/20 0.60
KDM4E B2RXH2 3/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
HCAR3 P49019 2/20 0.46
MEN1 O00255 2/20 0.39
POLB P06746 2/20 0.39
KMT2A Q03164 2/20 0.39
MAPT P10636 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CSNK2A1 P68400 5/20 0.37
GAA P10253 1/20 0.36
LMNA P02545 1/20 0.36
PDE5A O76074 2/20 0.35
CSNK2A2 P19784 1/20 0.35
CSNK2B P67870 1/20 0.35
RAB9A P51151 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
RECQL P46063 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4994161 0.95 ALDH1A1 (0.60) ALDH1A1HPGDKDM4ESMN1; SMN2HCAR3
SCHEMBL4990576 0.80 CSNK2A1 (0.54) ALDH1A1HPGDMEN1KMT2ACSNK2A1
SCHEMBL4991914 0.78 HCAR3 (0.41) ALDH1A1HPGDSMN1; SMN2HCAR3POLB
SCHEMBL5142171 0.78 HCAR3 (0.48) HCAR3CSNK2A1CSNK2A2CSNK2B
SCHEMBL12254173 0.77 KDM4E (0.48) ALDH1A1HPGDKDM4ESMN1; SMN2MEN1
SCHEMBL4991890 0.77 TSHR (0.50) ALDH1A1KDM4EPOLBMAPTGAA
Hydrochloric Acid SCHEMBL10456360 0.75 TSHR (0.48) ALDH1A1KDM4EPOLBMAPTGAA
SCHEMBL4986819 0.74 CSNK2A1 (0.51) ALDH1A1HPGDMEN1KMT2ACSNK2A1
SCHEMBL12254174 0.73 KDM4E (0.48) ALDH1A1HPGDKDM4ESMN1; SMN2MEN1
SCHEMBL4991719 0.72 HCAR3 (0.41) ALDH1A1HPGDKDM4ESMN1; SMN2HCAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349836-B2 Phthalazine derivatives as inhibitors of protein kinase ARALDI GIAN-LUCA (US) 2013-01-08 US claimed
US-20080146547-A1 PHTHALAZINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-19 US claimed
US-8349836-B2 Phthalazine derivatives as inhibitors of protein kinase ARALDI GIAN-LUCA (US) 2013-01-08 US disclosed
EP-2131656-A2 PHTHALAZINE DERIVATIVES Forest Laboratories Holdings Limited (BM) 2009-12-16 EP disclosed
US-20080146547-A1 PHTHALAZINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-19 US disclosed
WO-2008061108-A2 PHTHALAZINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146547-A1 PHTHALAZINE DERIVATIVES CDK5, HIPK2, PACSIN2 ALDH1A1 3613/4885HPGD 2226/4885KDM4E 761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.